ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, … after a single treatment with antisense oligonucleotide sepofarsen: a case report ” describing durable vision …
… Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 Study did not meet … 12. “Given the results observed in earlier studies of sepofarsen, the Illuminate trial results are unexpected and …
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Top-line results expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for … from the Company’s Phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for …
… ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data …
… Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Top-line data now expected to be announced in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the …
… Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Reported rapid, significant and … Illuminate, were more likely to respond to treatment with sepofarsen. Table: Change from baseline in treated eye …
